This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Click here for Trumenba® (meningococcal group B vaccine (recombinant, adsorbed)) Prescribing Information for Great Britain (GB) and Northern Ireland (NI). Adverse event reporting information can be found at the bottom of the page.

Meningococcal group B vaccine

Trumenba (meningococcal group B vaccine (recombinant, adsorbed)) is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B.1

Vaccinate with Trumenba to help protect adolescents and young adults from MenB disease.1

Trumenba is a vaccine composed of 2 recombinant lipidated factor H binding protein (fHbp) variants.1 fHbp is found on the surface of meningococcal bacteria and helps bacteria to avoid host immune defences.
fHbp variants segregate into 2 immunologically distinct subfamilies, A and B.1 Over 91%** of MenB strains express sufficient levels of fHbp subfamily A or B to be susceptible to bactericidal killing by Trumenba induced antibodies.

​​​**A survey of over 2,150 different invasive meningococcal serogroup B isolates collected from 2000-2014 in 7 European countries, the US and Canada demonstrated that over 91% of all meningococcal serogroup B isolates expressed sufficient levels of fHbp to be susceptible to bactericidal killing by vaccine-induced antibodies.1.

Trumenba offers two dosing schedules for adolescents and young adults1

Dosing Schedules

2-dose schedule1
This includes 2 doses (0.5ml each) administered 6 months apart.

3-dose schedule1
This includes 2 doses (0.5ml each) administered at least 1 months apart, followed by a third dose at least 4 months after the second dose.

Dosing considerations1

  • A booster dose should be considered following either dosing regimen for individuals at continued risk of IMD.
  • The use of this vaccine should be in accordance with official recommendations1

Trumenba can be co-administered concomitantly with​​​​​​​:

  • Quadrivalent Human Papillomavirus vaccine (HPV4)
  • Meningococcal Serogroups A, C, W, Y conjugate vaccine (MenACWY)
  • Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (Tdap)
  • Tetanus Toxoid, Reduced Diphtheria Toxoid, Acellular Pertussis, and Inactivated Poliovirus Vaccine (TdaP-IPV)
When given concomitantly with other vaccines Trumenba must be administered at a separate injection site.1 Trumenba should not be mixed with other vaccines in the same syringe.​​​​​​​

  1. Trumenba. Summary of Product Characteristics. Available at:​​​​​​​
PP-TRU-GBR-0140. February 2022.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021



OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?